Among these drugs, the FDA has approved two PD-1 antibodies (pembrolizumab and nivolumab) and three PD-L1 antibodies (atezolizumab, avelumab, and durvalumab) for use in cancer treatment [44]. Here, CD274 is linked to cancer.